With strong 1-year returns and upside potential, RAPT Therapeutics, Inc. (NASDAQ:RAPT) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. TD Cowen Initiates Coverage on RAPT Therapeutics (RAPT) with a “Buy” A dose bottle of the medication is in the medical tech's hand On December 18, 2025, The Fly reported that TD Cowen initiated coverage of RAPT Therapeutics, Inc. (NASDAQ:RAPT) with a “Buy.” The bullish stance reflects the potential of the company’s lead candidate, o ...

With strong 1-year returns and upside potential, Ventyx Biosciences, Inc. (NASDAQ:VTYX) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. Analysts Bullish as Ventyx Biosciences (VTYX) Advances Its Clinical and Strategic Initiatives As of December 18, 2025, 90% of analysts are bullish on Ventyx Biosciences, Inc. (NASDAQ:VTYX), setting a median price target of $14.00. This translates into a massive upside potential of 82.05%. Amid this bullish momentum, Ventyx Bioscien ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the 12 best multibagger stocks to buy heading into 2026. Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress As of December 18, 2025, 90% of analysts are bullish on CytomX Therapeutics, Inc. (NASDAQ:CTMX), setting a median price target of $6.50. This translates into a healthy upside potential of 58.20%. On December 5, 2025, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw H.C. Wainwright reiterate its “Buy” rating wit ...

With strong 1-year returns and upside potential, DBV Technologies S.A. (NASDAQ:DBVT) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. H.C Wainwright and Citizens Raise PT on DBV Technologies (DBVT) Following Phase 3 VITESSE Trial Result On December 17, 2025, H.C. Wainwright raised its price target on DBV Technologies S.A. (NASDAQ:DBVT) from $35 to $40, while reiterating a “Buy” rating, The Fly reported. The firm described the Phase 3 VITESSE trial as a clear executio ...

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 12 best multibagger stocks to buy heading into 2026. Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment On December 3, 2025, Compass Therapeutics, Inc. (NASDAQ:CMPX) saw Canaccord analyst John Newman initiate coverage of the stock with a “Buy” rating and a $10 price target. The analyst attributed the bullish stance to positive data in the first quarter of 2026 from second-line biliary tract cancer studies. Newman sees tovecimig as ...

Fstop123 | E+ | Getty ImagesFor homebuyers, getting one preapproval for a mortgage that has palatable terms may seem good enough. More than two-thirds — 69% — of homebuyers submit only one mortgage application, according to a new report from Zillow.However, you shouldn't stop there, experts say. With the average interest rate on a traditional 30-year mortgage sitting above 6.2% as of Friday, even a half-point difference in the rate can be a game-changer for some homebuyers, who already face elevated prices ...

Group 1 - The article discusses the importance of in-depth research on various investment vehicles including REITs, mREITs, Preferreds, BDCs, MLPs, and ETFs, emphasizing the potential for income generation [1] - Leo Nelissen is highlighted as an analyst focusing on economic developments related to supply chains, infrastructure, and commodities, aiming to provide actionable investment ideas with a focus on dividend growth opportunities [1] Group 2 - The article includes a disclosure indicating that the author has a beneficial long position in specific stocks, which may influence the analysis presented [2] - It is noted that past performance is not indicative of future results, and no specific investment recommendations are made, emphasizing the independent nature of the analysis [3]

If you’re approaching retirement with a sense of dread and unease, you’re not alone. Roughly 65% of retirement savers surveyed by global investment manager Schroders said they worry about money too much (1). Another 56% said their financial stress could even have an impact on their health. So if you’re worried sick about healthcare costs, inflation, lack of savings and interest rates, those feelings are perfectly normal. Still, if you’re retiring after hitting certain benchmarks, it could be a signal that ...

“I think the general [headcount] trend in the banking industry over the last decade is stable to slightly declining. I don’t see that changing anytime soon,” Pim Hilbers, a managing director working with banking and talent at BCG, tells Fortune. “That doesn’t mean that everybody just stays in their job for life. I think we see a lot more mobility than we saw in the past.”Despite Wall Street making headlines for its relentless string of layoffs this year, headcounts across banking and finance have actually b ...

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting with competent advisors before making any financial decisions, particularly in the context of investments in complex instruments like cryptocurrencies and CFDs [1]. Group 1 - The website provides general news, personal analysis, and third-party materials intended for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as a recommendation or advice for investment actions [1]. - The accuracy and reliability of the information are not guaranteed, and users are cautioned against relying solely on the content provided [1]. Group 2 - The website discusses the high risks associated with cryptocurrencies and CFDs, highlighting their complexity and the potential for significant financial loss [1]. - It encourages users to conduct their own research and fully understand the instruments and risks involved before making investment decisions [1].